Election 2024 In surely the most dramatic comeback in US political history, Donald Trump has secured a second term as president of the United States. Trump will be sworn in on January 20, 2025, and we'll be following all the major stories in the lead-up to Inauguration Day. Sign up no...
Elaine K. HowleyandC.J. Trent-GurbuzFeb. 18, 2025 Wellness Zepbound: What You Need to Know The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its potential side effects and why it’s not a substitute for a healthy ...
Polls remain the lifeblood of any candidate's run — and a critical factor in presidential betting odds. Endorsements, debate performances, primary results and a host of other factors can influence poll respondents' answers, but the results of the polls themselves have major impacts on how bookmak...
It’s time to dump the party primary system that shuts out millions of voters. Nick TroianoNov. 1, 2024 What $16B Bought in the 2024 Campaign The end of a historically expensive 2024 election cycle is finally in sight. Here’s how the candidates and their allies have spent their billions...
I’ve been having good results. . . . That will cause me to splurge a little bit, because it makes me confident that I’m getting some extra money, and it’s a little different from earlier in 2024, because I didn’t have as much money. ...
Hallie CrawfordDec. 20, 2024 Careers 5 Workplace Trends Workers Hate Bosses love these trends while employees tend to loathe them. Robin MadellDec. 18, 2024 This website uses cookies to enhance user experience, analyze performance and traffic on our website and provide personalized content and ...
Who are the primary users of your Machine Learning application for the US elections 2024? Are they political campaigners or party organizations? Or advocacy groups or individual candidates other than voters? You need to understand their requirements, preferences, and pain areas to develop the US El...
EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli...
Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group trial GOG-0199. J Clin Oncol. 2014;32(29):3275-3283. doi:10.1200/JCO.2013.54.1987PubMedGoogle ScholarCrossref 6. Norquist BM, Garcia RL, Allison KH, et al. The molecular pathogenesis ...
Datasets for characterizing extreme events relevant to hydrologic design over the conterminous United States Article Open access 05 April 2022 Bracing for impact: how shifting precipitation extremes may influence physical climate risks in an uncertain future Article Open access 29 July 2024 Introduction...